Covered and uncovered biliary metal stents provide similar relief of biliary obstruction during neoadjuvant therapy in pancreatic cancer: a randomized trial

Short Title: Biliary metal stents in neoadjuvant therapy

Dong Wan Seo¹; Stuart Sherman²; Kulwinder S. Dua³; Adam Slivka⁴; Andre Roy⁵; Guido Costamagna⁶; Jacques Deviere⁷; Joyce Peetmans⁸; Matthew Rousseau⁸; Yousuke Nakai⁹; Hiroyuki Isayama⁹*, and Richard Kozarek¹⁰ for the “Biliary SEMS during neoadjuvant therapy study group”

Authors’ affiliations:

1. Internal Medicine, Asan Medical Center University of Ulsan, Seoul, South Korea
2. Division of Gastroenterology and Hepatology Indiana University School of Medicine, Indianapolis, Indiana, United States
3. Gastroenterology and Hepatology, Medical College of Wisconsin, Milwaukee, Wisconsin, United States
4. Gastroenterology, Hepatology and Nutrition, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
5. Surgery, Centre hospitalier de l'Université de Montréal, Montreal, Quebec, Canada
6. Fondazione Policlinico A. Gemelli - IRCCS, Digestive Endoscopy Unit, Roma, Italy; Università Cattolica del S. Cuore, Roma, Italy
7. Gastro-Entérologie et d’Hépato-Pancréatologie, Universite Libre de Bruxelles Hôpital Erasme, Brussels, Belgium
8. Boston Scientific Corporation, Marlboro, Massachusetts, United States
9. Gastroenterology, University of Tokyo, Tokyo, Japan*
10. Digestive Disease Institute, Virginia Mason Medical Center, Seattle, Washington, United States

* Current institutional affiliation for Hiroyuki Isayama is Graduate School of Medicine, Juntendo University, Tokyo, Japan

This is the author's manuscript of the article published in final edited form as:

**Word Count**: 3,818

**Corresponding authors’ contact information:**

*Please note there are two corresponding authors:*

Dr. Richard Kozarek  
Virginia Mason Medical Center  
1100 Ninth Ave.  
Seattle, WA 98101  
Richard.Kozarek@virginiamason.org  
Tel: +1-206-399-6716  Fax: +1-206-341-0180

Professor Dong Wan Seo, M.D.  
Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine  
388-1 Pungnapdong, Songpagu, Seoul, Korea  
Tel: +82 2 3010 3190 Fax: +82-2-485-5782  
email: dwseoamc@amc.seoul.kr
A randomized comparison of covered versus uncovered biliary metal stents during neoadjuvant therapy in pancreatic cancer

Short Title: Biliary Metal Stents in Neoadjuvant Therapy

Dong Wan Seo1; Stuart Sherman2; Kulwinder S. Dua3; Adam Slivka4; Andre Roys; Guido Costamagna5; Jacques Deviere7; Joyce Peetermans8; Matthew Rousseau; Yousuke Nakai9; Hiroyuki Isayama9*, and Richard Kozarek10 for the “Biliary SEMS during neoadjuvant therapy study group”
Abstract

**Background and Aims:** Preoperative biliary drainage with self-expanding metal stents (SEMSs) brings liver function within acceptable range in preparation for neoadjuvant therapy (NATx) and provides relief of obstructive symptoms in patients with pancreatic cancer. We compared fully covered SEMSs (FCSEMSs) and uncovered SEMSs (UCSEMSs) for sustained biliary drainage before and during NATx.

**Methods:** Patients with pancreatic cancer and planned NATx needing treatment of jaundice and/or cholestasis before pancreaticoduodenectomy were randomized to FCSEMS versus UCSEMS. Primary endpoint was sustained biliary drainage, defined as absence of reinterventions for biliary obstructive symptoms, and was assessed from SEMS placement until curative intent surgery (CIS) or 1 year.

**Results:** The intent-to-treat population had 119 patients (59 FCSEMS, 60 UCSEMS). Sustained biliary drainage was equally successful with FCSEMS and UCSEMS (72.2% vs 72.9%, noninferiority P=0.01). Reasons for FCSEMS and UCSEMS failure differed significantly between groups and included tumor ingrowth in 0 versus 16.7%, P<0.01, and stent migration in 6.8% vs. 0, P=0.03, respectively. Serious adverse event rates related to stent placement were insignificantly different in both groups (23.7% (14/59) vs 20.0% (12/60), P=0.66), as were acute cholecystitis rates when gallbladder in situ (9.3% (4/43) vs 4.8% (2/42), P=0.68) for FCSEMSs and UCSEMSs, respectively. In our study, independent of stent type, predictors of reinterventions were 4 cm stent length and presence of gallbladder.

**Conclusion:** FCSEMSs and UCSEMSs provide similar preoperative management of biliary obstruction in pancreatic cancer patients receiving NATx, but mechanisms of stent dysfunction depend on stent type, stent length, and presence of the gallbladder.

**Key Words:** pancreatic cancer; biliary obstruction; fully covered self-expanding metal stents; uncovered self-expanding metal stents; neoadjuvant therapy; preoperative management.

**Clinical Trial Registration:** ClinicalTrials.gov NCT02238847
Introduction

In the United States, pancreatic cancer is the second most common digestive cancer and the fourth leading cause of cancer death, with a 5-year survival rate of only 6%.(1) Approximately 70% of patients with pancreatic cancer present with biliary obstruction,(2) and those with borderline resectable, locally advanced, or even resectable tumors often undergo preoperative neoadjuvant therapy (NATx) to downsize the tumor, provide early treatment of micrometastases, and ultimately optimize post-operative survival.(3-7) Preoperative biliary drainage mainly aims to resolve jaundice and bring elevated liver function tests (LFTs) within acceptable range so that NATx may be initiated, and maintain relief of biliary obstructive symptoms during NATx.(8, 9) The latter decreases the risk of inciting an inflammatory cascade in severely jaundiced patients,(10) and reduces the risk of adverse events from inadequate drainage, such as cholangitis.(11) Without effective preoperative drainage, patients may experience interruption of the NATx and/or delayed surgery.

Uncovered (UC) and fully covered (FC) self-expanding metal stents (SEMS) were shown to be superior to plastic stents for preoperative biliary drainage due to increased stent patency.(12-16) FCSEMSs were developed to prevent tissue ingrowth. Several meta-analyses assessed UCSEMSs versus FCSEMSs, and although most have shown no differences in stent patency or patient survival, conflicting results were reported for rates of SEMS migration, tumor ingrowth, tumor overgrowth, and acute cholecystitis.(17-22) Both FCSEMSs and UCSEMSs used in this study are cleared for palliative treatment of malignant biliary strictures and relief of biliary obstruction before surgery. The FCSEMS is also indicated for treatment of some benign biliary strictures. Thus, FCSEMS given their removable attribute, can offer on-label advantages in the setting of biliary strictures of indeterminate etiology. We sought to assess in a prospective randomized fashion whether this FCSEMS was noninferior to the UCSEMS for preoperative sustained biliary drainage in pancreatic cancer patients with planned NATx before curative intent pancreaticoduodenectomy. We deemed this study would lead to benefit in clinical practice if noninferiority of a FCSEMS was demonstrated. As such, if an FCSEMS was chosen because a biliary stricture was indeterminate, a subsequent diagnosis of underlying malignancy should not entail FCSEMS exchange for an UCSEMS (because of concern for stent migration or development of cystic duct obstruction and cholecystitis). Although the study was not powered
to compare the rate of incidence of adverse events that are particularly feared in this immunosuppressed population, we documented adverse event rates carefully to rule out major differences between FCSEMS and UCSEMS groups.

Methods

Design
In this international, prospective, multicenter trial (ClinicalTrials.gov NCT02238847), we randomized patients in a 1:1 ratio to preoperative biliary drainage with a FCSEMS versus UCSEMS (WallFlex Biliary RX Fully Covered and Uncovered Stent, Boston Scientific, Marlborough, Mass). Block randomization was performed via an online database accessed on site at the start of the procedure. Randomization was stratified by study site. At each site concealed envelopes were used as the back-up randomization system.

Each participating institution’s Ethics Committee/Institutional Review Board approved the study and each patient gave written informed consent. All authors had access to the study data and reviewed and approved the final manuscript.

The study stent system consists of a flexible delivery system preloaded with a radiopaque SEMS with flared ends. The FCSEMS is covered with a Permalume Coating (translucent silicone polymer) and has a retrieval loop for removal, neither features being contained in the UCSEMS. Selection of stent length and diameter were at the discretion of the Investigator.

Patients and Procedures
Patients with pancreatic cancer scheduled for NATx and needing preoperative biliary drainage before curative intent surgery (CIS) were screened for study eligibility. The location of the biliary stricture had to allow for the proximal end of the SEMS to be positioned at least 2 cm below the hilum to assure enough not previously stented bile duct for dissection and anastomosis during surgery. Patients were treated with NATx per local standard of medical oncology. Patients who proceeded to CIS were followed for 30 days post-surgery and their survival status was checked at 1 year. Patients who did not reach CIS proceeded to nonoperative, palliative care and were followed to 1 year after biliary SEMS placement.
Endpoints
The primary endpoint was sustained biliary drainage, defined as absence of reinterventions for the management of biliary obstructive symptoms, assessed from SEMS placement until CIS when applicable or to one year after SEMS placement otherwise.

Secondary endpoints included technical success defined as ability to deploy the stent in a satisfactory position across the stricture, ability to complete NATx as intended without stent-related interruptions of NATx and without biliary reintervention, subjective impression of the surgeon that the presence of a SEMS may have impacted the surgical procedure, and serious adverse events (SAEs) related to the stent and/or stent placement procedure, up to 30 days after surgery where applicable or 1 year after stent placement for patients not undergoing surgery. Adverse events (AEs) were predefined as detailed in Appendix 1. Also assessed were mortality at one year after randomization and incidence of stent migration, stent occlusion due to tumor ingrowth, and acute cholecystitis as causes for reintervention, and improvement of liver function tests (LFTs) until surgery for patients undergoing surgery and until 1 year after stent placement for patients not undergoing surgery.

Statistical Methods
Statistical testing was performed to determine if the rate of attaining sustained biliary drainage when using the FCSEMS was noninferior to the rate when using the UCSEMS. A noninferiority design was selected because preoperative biliary drainage was first described using UCSEMS, but there have been no RCTs to establish if FCSEMS are, in fact, noninferior. This question is relevant because there were reports that FCSEMS have a higher risk of stent migration and of causing acute cholecystitis when the cystic duct confluence is covered by the FCSEMS, whereas it was also reported that UCSEMS are associated with risk of occlusion due to tumor ingrowth.

A meta-analysis of 9 pertinent articles representing 377 patients,(13, 15, 23-29) yielded a success rate estimate of 84.6% (95% confidence interval [CI], 80.5%-87.9%). Assuming the success rate of each arm was 80.5%, a sample size of 102 patients would provide 80% power to reject the null hypothesis that FCSEMSs are inferior to UCSEMSs, using a noninferiority margin of 20% and an exact noninferiority test with significance level of ≤0.05. Allowing for attrition, enrollment was capped at 120 patients. The 20% noninferiority margin was chosen to support a practical study size while still able to identify major differences in performance if this were the
case. Although this margin may seem high, if FCSEMS were worse than UCSEMS by more than approximately 7% in this trial with 120 patients, the hypothesis would fail to be proven.

Analyses were performed on all randomized patients according to the intention-to-treat (ITT) and per protocol (PP) principles.(30) The ITT group included all randomized patients. The PP group included all patients who were treated per protocol and had no major protocol deviations per International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use guidelines. Patients eligible for primary endpoint analysis within the ITT analysis excluded those who died, withdrew consent, or were lost to follow-up before CIS or 1 year as applicable.

Continuous baseline characteristics are presented as median with interquartile range (IQR) and compared between groups using the Wilcoxon rank-sum test. Categorical characteristics are presented as counts and percentages and compared between groups using the Fisher exact test, with corresponding Clopper-Pearson 95% CIs, where applicable. Kaplan-Meier estimates of endpoint events were calculated for each treatment group and tested using the log-rank test with Greenwood’s 95% CIs, where applicable.

Univariate and multivariate analyses were performed to assess the effect on the primary endpoint of randomization group, age, gender, baseline bilirubin, alkaline phosphate, weight, and Karnofsky score,(31) stent length 4 cm, tumor location, tumor size, tumor stage, and whether chemotherapy included Gemcitabine using Cox proportional hazards regression. Stepwise selection was performed to build the multivariate model, with entry and exit set at P>0.1, and randomized group was forced to stay in model regardless of P value. SAS version 9.4 and StatXact version 11 were used for all analyses. P<0.05 was considered significant for all analyses.

**Results**

**Study Population**

Patients were enrolled between March 2015 and April 2017 at 9 institutions in Belgium (1), Canada (1), Italy (1), Japan (1), Korea (1), United States (4). Of 136 screened patients, 17 were not eligible for randomization, and 119 were randomized (59 to FCSEMS, 60 to UCSEMS) comprising the ITT cohort. Of these, 113 patients were eligible for primary endpoint analysis.
Two patients, one in each arm, received the stent type not attributed by randomization; thus 111 patients comprised the PP cohort. Six patients were not evaluable for primary endpoint analysis. One patient withdrew consent immediately after uneventful placement of a FCSEMS. Two patients died before potential CIS, one on day 40 of progression of pancreatic cancer after UCSEMS placement, and one on day 44 from iatrogenic causes related to chemotherapy without stent-related adverse events with confirmed FCSEMS patency on CT and ERCP. Three patients were lost to follow-up after placement of a FCSEMS on day 14 day 38, and day 283 without stent-related adverse events and with improved LFTs at last visits.

Of the 113 patients eligible for primary endpoint analysis, 51 (45.1%) patients underwent CIS and 62 (54.9%) patients did not (Figure 1).

Median follow-up for ITT primary endpoint analysis was 206 days (IQR 126-327) overall, 207 days (IQR 136-336) in the FCSEMS group, and 197 days (IQR 121-320) in the UCSEMS group (P=0.58).

There were no significant differences in baseline characteristics between groups (Table 1) except for the Karnofsky score. Six patients had a low Karnofsky score of 50 or 60, 5 in the UCSEMS and one in the FCSEMS group. Tissue diagnosis was made by EUS fine-needle aspiration or biopsy (EUS-FNA/FNB) in the majority (111/119, 93.3%) and ductal biopsy and/or brushing in a few patients (8/119, 6.7%). All patients had pancreatic adenocarcinoma, more than 30% stage IIA and approximately 25% stage IIB.

Stents and Technical Success

Technical success of stent placement was 99.2%, resulting in 120 SEMS placed in 119 patients. One patient failed technical success of FCSEMS placement, positioned too far into the bile duct, but with its proximal end still below the hilum. Intraprocedural repositioning was not possible and a second FCSEMS was placed inside the first one in a transpapillary position. The patient did not undergo CIS and was followed to 1 year without SEMS-related adverse events or reinterventions.

There was no difference in size of stents used between groups (P=0.52). The great majority (115 (96.6%)) were 10 mm in diameter. SEMS length was 6 cm in 85 (71.4%) and 4 cm in 32 (26.9%) (Table 1). A 4 cm stent length was selected in 14 of 32 (43.8%) FCSEMS and 18 of 32 (56.2%)...
UCSEMS (P=0.50); thus, randomization did not significantly impact the decision to select a 4-
cm stent. However, 30 of 32 (93.8%) 4-cm-length stents were selected in significantly more
patients with gallbladder in situ compared with 2 of 32 (6.2%) for patients with a prior
cholecystectomy (P<0.01).

**Sustained biliary drainage - Primary Endpoint**

Sustained biliary drainage assessed in 113 patients in the primary endpoint ITT cohort was
reached in 72.2% (39/54) of patients with FCSEMS versus 72.9% (43/59) of patients with
UCSEMS (P=0.01) as tested to the noninferiority margin of 20% (Table 2), also demonstrated
by the 95% upper 1-sided CI limit of 14.8%. The 95% CI of difference also did not include the
20% margin and was 0.7% (-16.0% to 17.5%).

A tipping point sensitivity analysis was conducted to assess the effect of missing data in the
FCSEMS test arm by counting them as endpoint failures and eliminating the patient who
withdrew consent on Day 0. In this analysis, successful decompression would have been 67.2%
(39/58) in the FCSEMS versus 72.9% (43/59) in the UCSEMS group (P=0.05) as tested to the
pre-study noninferiority margin of 20%, thus still proving noninferiority.

In the PP cohort sustained biliary drainage was attained in 71.7% (38/53) in the FCSEMS and in
72.4% (42/58) in the UCSEMS group (P=0.01) as tested to the 20% noninferiority margin.

Likewise, FCSEMS was noninferior to UCSEMS in the analysis of 51 patients eligible for the
primary endpoint who underwent CIS (83.3% vs. 81.5%, noninferiority P=0.03). For the 62
patients who did not undergo CIS and were followed for 1 year, there was a nonsignificant
difference (63.3% vs 65.6%, noninferiority P=0.09).

The Kaplan-Meier analysis of ITT patients, in which all 119 patients contribute until the time of
failure, death, loss to follow-up, or withdrawal of consent, demonstrated that sustained biliary
drainage at 6 months after randomization had a probability of 77.5% (95% CI, 65.3%-89.7%) for
the FCSEMS group and 80.5% (95% CI, 69.3%-91.8%) in the UCSEMS group, and at 1 year
had a probability of 61.0% (95% CI, 43.4%-78.7%) in the FCSEMS group versus 51.4% (95%
CI, 28.2%-74.6%) in the UCSEMS group (P=0.97). In the subgroup of patients that underwent
CIS, a Kaplan-Meier analysis of biliary decompression showed success at 6 months in 83.3%
(95% CI, 68.4%-98.2%) in the FCSEMS group and in 84.1% (95% CI, 69.8%-98.4%) in the
UCSEMS group. In the subgroup of patients that did not undergo CIS, the same analysis showed
success in 74.9% (95% CI, 58.7%-91.2%) in the FCSEMS group and in 78.9% (95% CI, 63.7%-94.2%) in the UCSEMS group. The Kaplan-Meier analyses are shown in Figure 2 for the overall ITT cohort, and in Supplementary Figures 1 and 2 respectively for the subset of patients who underwent and did not undergo CIS.

Mean bilirubin levels in the FCSEMS and UCSEMS groups responded from elevated levels before stent placement to rapid normalization maintained after stent placement until the end of follow-up, with a similar time response in both groups, as shown in Supplementary Figure 3.

**Neoadjuvant Therapy and Curative Intent Surgery**

No significant differences were observed between the FCSEMS and UCSEMS groups as it pertains to NATx and CIS (Table 2).

Thirteen patients transitioned to palliative management (7) and died while on study or received CIS (6) between day 8 and day 63 after SEMS placement before the planned NATx was initiated.

The rate of patients who completed NATx with delays with recurrent biliary obstruction requiring reintervention was similar in the FCSEMS and UCSEMS groups (P=0.99).

The rate of patients undergoing CIS was 51 of 113 (45.1%) overall, and insignificantly different between groups (P=0.85). The median time to CIS was 110 days, also insignificantly different between groups.

The empiric impression of the surgeon that the presence of a SEMS may have impacted the surgical procedure was similar in the FCSEMS and UCSEMS group (P=0.99) and did not appear to be related to stent length.

**Adverse events and reinterventions**

Overall procedure or SEMS-related SAEs occurred in 23.7% (14/59) in the FCSEMS versus 20.0% (12/60) in the UCSEMS group (P=0.66) (Table 2). Of these 26 related SAEs, 24 resulted in a reintervention. In addition, 7 non-serious AEs resulted in a reintervention. Thus in total there were 31 reinterventions that are listed, including the cause for the reintervention and the type of reintervention in Supplementary Table 1.

For 23 cases of cholangitis and/or biliary obstructive symptoms, the reported causes were 10 UCSEMS ingrowth, 3 FCSEMS and 2 UCSEMS occlusion by sludge or necrotic debris, 4
FCSEMS migration, 1 FCSEMS and 1 UCSEMS overgrowth, 1 UCSEMS kinking, and 1 FCSEMS had no observed SEMS occlusion or migration. For 6 cases of acute cholecystitis, the presumed cause was cystic duct confluence occlusion by the UCSEMS (2) or FCSEMS (4). Reinterventions for 10 UCSEMS ingrowth cases were SEMS-in-SEMS placement (8), percutaneous transhepatic biliary drainage (1), or biliary radiofrequency ablation (1). For the 6 cases of acute cholecystitis, the associated reintervention was placement of a percutaneous cholecystostomy tube (4), exchange of the FCSEMS by an UCSEMS (1) or cholecystectomy (1). All 5 cases of FCSEMS migration underwent FCSEMS exchange for another stent. Among the 5 cases of SEMS occlusion by sludge or necrotic debris, FCSEMS were removed and exchanged for another stent (4) or sludge was simply removed from an UCSEMS (1). The case of a gastrointestinal bleed was reported as most likely caused by partial migration over two-thirds of the length of the FCSEMS into the duodenum. The blood clot was left in place and the FCSEMS was removed and exchanged for an UCSEMS 1 month later.

Comparing the FCSEMS and UCSEMS groups, there were significant differences in reasons for SEMS failure between groups (Figure 3), notably tumor ingrowth at 0% and 16.7% (P<0.01), and stent migration in 6.8% and 0% (P=0.03), respectively. Incidence of acute cholecystitis was insignificantly different between FCSEMS and UCSEMS groups, namely respectively 9.3% (95% CI, 2.6% - 22.1%) and 4.8% (95% CI, 2.6% - 14.7%) with a difference of 4.5% (95% CI, 8.1% - 18.2%; P=0.68). One case of acute cholecystitis occurred on day 53 after FCSEMS placement and was associated with proximal FCSEMS migration.

A Kaplan-Meier analysis of survival to 1 year shows no difference between FCSEMS group 60.2% versus 56.8% in the UCSEMS group (P=0.57; Figure 4).

**Predictors of Sustained Biliary Drainage**

Significant predictors of failure to attain sustained biliary drainage included use of a stent with a length of 4 cm (as opposed to 6 or 8 cm) and if the gallbladder was in situ. Univariate analysis showed a hazard ratio [HR] 2.9 (95% CI, 1.4-6.0; P<0.01) if the patient had a 4 cm stent and a HR of 8.6 (95% CI, 1.6-45.7; P=0.01) if the gallbladder was present. In a multivariate analysis, 4 cm stent length had a HR of 2.1 (95% CI, 1.0-4.3; P=0.05) and gallbladder in situ had a HR of 6.9 (95% CI, 1.3-37.8; P=0.03; Figure 5).
Discussion

This prospective multinational trial enrolled patients scheduled for NATx before CIS. All patients had pancreatic adenocarcinoma, confirmed by EUS FNA/FNB, ductal biopsy or brushing before enrollment in this study. All but 6 patients had a Karnofsky score of 70 or better.

Patients were randomized to biliary decompression using a FCSEMS or an UCSEMS. FCSEMSs were shown to be noninferior to UCSEMSs for sustained biliary drainage on an ITT basis until CIS or to 1 year (72.2% vs. 72.9%, noninferiority P=0.01). A Kaplan-Meier analysis at 1 year after randomization confirms insignificant differences in sustained biliary drainage and shows similar times to reintervention when using FCSEMSs or UCSEMSs.

Concerns have been raised about tissue ingrowth requiring reintervention when using UCSEMSs, and of migration and acute cholecystitis when using FCSEMSs(32), either of which can guide stent type choice by the endoscopist. Of 31 patients experiencing SEMS failure requiring reintervention before CIS or before 1 year in patients who do not undergo CIS there were significant differences in reasons for SEMS failure between groups. Tumor ingrowth requiring intervention was significantly more likely in the UCSEMS than in the FCSEMS group (P<0.01). For stent migration the opposite was true (P=0.03). Acute cholecystitis had a nonsignificant tendency to occur more frequently when using FCSEMSs (P=0.68).

Improper stent functionality causing delays or noncompletion of chemotherapy were not different for FCSEMS and UCSEMS. There was also no difference between the FCSEMS versus UCSEMS groups in time to CIS (114 vs 106.5 days, P=0.94). This establishes that the UCSEMS and FCSEMS choices are insignificantly different in providing proper biliary drainage during NATx.

In our study, the only significant predictors of failure to decompress biliary obstruction were SEMS of 4 cm length compared to 6 cm and 8 cm length and the presence of a gallbladder. Increased risk of failure occurred with a multivariate HR of 2.1 for SEMS of 4cm length compared to 6 cm and 8 cm length, and HR of 6.9 for patients with gallbladder in situ. It is noteworthy that selection of the 4 cm stent length was significantly more common among patients with gallbladder in situ compared to patients with a prior cholecystectomy (P<0.01).
In a recent retrospective cohort study with 645 patients, covered SEMSs (CSEMs) and UCSEMSs had similar rates of clinical success in relief of bile duct obstruction and patency duration; however, among those with gallbladder in situ, CSEMS use was associated with increased acute cholecystitis; and in multivariable analysis, CSEMS use was associated with increased migration. (32) A retrospective series from Korea published in 2006 (33) concluded that acute cholecystitis occurred in 15 of 155 (9.7%) patients receiving SEMS for management of malignant biliary obstruction and was more likely when the tumor involved the cystic duct confluence. Also in 2006 (34) a Japanese retrospective series in 246 patients with unresectable distal malignant bile duct strictures receiving 171 CSEMs and 75 UCSEMSs, 13 (5.3%) of patients developed acute cholecystitis, confirming association with tumor involvement at the cystic duct orifice, but not associated with CSEMS or UCSEMS type. More recently, in 2014, the same group in Japan (35) analyzed risk factors for CSEMS migration in a retrospective series of 290 patients and concluded that CSEMS migration occurred in 15.2%, associated with low radial force of the CSEMS, administration of chemotherapy, and duodenal tumoral involvement.

Given comparable success rates of preoperative biliary decompression before and during NATx in pancreatic cancer patients and given that the price of the FCSEMS is higher than that of UCSEMSs in several markets, the removable aspect of the FCSEMS should be emphasized in settings of uncertain diagnosis and uncertain patient management plan. When cancer is not proven, FCSEMS placement can prevent, for example in autoimmune pancreatitis, the potential disaster of having placed an UCSEMS in a benign biliary stricture. If a FCSEMS was placed in the case of indeterminate biliary strictures and malignancy is subsequently confirmed, exchange of the FCSEMS for an UCSEMS is not warranted given findings of our study.

There are several limitations to this study. Firstly, the study was fairly small, thus conclusions could be drawn from the primary endpoint, but analyses pertaining to different site-by-site medical oncology treatment regimens were not possible. Secondly, 2 patients, 1 per group, were not treated as randomized. Fortunately, a sensitivity analysis of this discrepancy between the ITT and PP analyses confirmed that this had no effect on the primary endpoint analysis. Last, this study was sponsored by the manufacturer of the UCSEMS and FCSEMS used in the study. An effort was made to mitigate unwanted bias by assuring data sharing and strong collaboration and oversight by the investigators throughout the study, from protocol development through data analyses and manuscript writing and review. Key representatives of the manufacturer
participated in these processes and hence are featured in the author list. Although this study was supported by the manufacturer of the SEMS used in this study, the Wallflex Biliary UCSEMS and FCSEMS are the only ones marketed in the United States and cleared by the FDA for relief of malignant biliary obstruction before surgery.

In conclusion, this international randomized study demonstrated noninferiority of FCSEMS compared to UCSEMS for preoperative management of biliary obstruction in pancreatic cancer patients in the setting of NATx. Mechanisms of stent dysfunction depended on stent type—FCSEMS or UCSEMS—and attaining sustained biliary drainage depended on stent length and presence of gallbladder.

Financial Support and Acknowledgements

This study was sponsored by Boston Scientific Corporation.

The authors who conducted study procedures acknowledge their sub-investigators Dr. Dongwook Oh\(^1\), Dr. Evan Fogel\(^2\), Dr. Jeff Easler\(^2\), Dr. Glen Lehman\(^2\), Dr. James Watkins\(^2\), Dr. Lee McHenry\(^2\), Dr. Ihab El-Hajj\(^2\), Dr. Abdul Khan\(^3\), Dr. Murad Abu Rajab\(^3\), Dr. Darren Ballard\(^4\), Dr. Georgios Papachristou\(^4\), Dr. Mordechai Rabinovitz\(^4\), Dr. Simon Bouchard\(^5\), Dr. Marylène Plasse\(^5\), Dr. Andrea Tringali\(^6\), Dr. Ivo Boskoski\(^6\), Dr. Vincent Huberty\(^7\), Dr. Pierre Eisendrath\(^7\), Dr. Marianna Arvanitakis\(^7\), Dr. Vincent Picozzi\(^10\), Dr. Shayan Irani\(^10\), Dr. Michael Larsen\(^10\), and Dr. Andrew Ross\(^10\). Together they comprise the “Biliary SEMS during neoadjuvant therapy study group”. Professor Hiroyuki Isayama and Professor Dong Wan Seo served as lead investigators during the conduct of the trial. They also wish to thank Joanna Suomi for her expert contributions to this manuscript as a medical writer. The authors that are Boston Scientific Corporation employees acknowledge contributions to study conduct and safety review by their colleagues Lina Ginnetti, Nguyet Nguyen, and Dr. Thomas Bowman.
Tables and Figures

**Figure 1. Patient Flowchart.**
Abbreviations: CIS, curative intent surgery; FCSEMS, fully-covered, self-expanding metal stents; ITT, intention-to-treat; UCSEMS, uncovered, self-expanding metal stents. Enrollment cap was N=120 patients, but one patient was removed from the ITT cohort because of treatment with a SEMS before randomization.
*Deaths due to disease progression/neoadjuvant therapy.

**Figure 2. Kaplan-Meier analysis of primary endpoint in the intention-to-treat analysis set.**
Kaplan-Meier curves are shown for the primary endpoint, namely sustained biliary drainage, according to randomized treatment arm in an ITT analysis with intended follow-up to CIS where applicable, or to 1 year otherwise. Sustained biliary drainage occurred in 61.0% of patients with FCSEMS versus 51.4% of patients with UCSEMS at 1 year (P=0.84) in an analysis of all N=119 patients.
Abbreviations: CI, confidence interval; DBO, sustained biliary drainage; FC, fully-covered; UC, uncovered.

**Figure 3. Principal reasons for reintervention during the index procedure by randomized treatment group.** Abbreviations: FCSEMS, fully covered self-expanding metal stents; UCSEMS, uncovered self-expanding metal stents.

**Figure 4. Kaplan-Meier Analysis of Survival to 1 Year.**
Kaplan-Meier curves are shown for survival to 1 year according to randomized treatment arm. 60.2% of patients in FCSEMS group versus 56.8% of patients with UCSEMS at 1 year (P=0.57).
Abbreviations: CI, confidence interval; FC, fully covered; UC, uncovered.

**Figure 5. Predictors of failure to attain sustained biliary drainage.** Univariate and multivariate analysis of failure to attain sustained biliary drainage. Abbreviations: SEMS, self-expanding metal stent.
Table 1. Baseline characteristics.

Baseline characteristics are presented for the intention-to-treat cohort.

<table>
<thead>
<tr>
<th>Patient characteristics*</th>
<th>FCSEMs N=59</th>
<th>UCSEMs N=60</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>67.0 (IQR 58.0-71.0)</td>
<td>65.0 (IQR 58.5-73.0)</td>
<td>0.89</td>
</tr>
<tr>
<td>Male</td>
<td>55.9% (33/59)</td>
<td>55.0% (33/60)</td>
<td>0.99</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>77.7 (IQR 62.3-87)</td>
<td>78.4 (IQR 65.1-90.4)</td>
<td>0.47</td>
</tr>
<tr>
<td>Gallbladder in Situ</td>
<td>72.9% (43/59)</td>
<td>70% (42/60)</td>
<td>0.84</td>
</tr>
<tr>
<td>Karnofsky Score</td>
<td>90.0 (IQR 80.0-100.0)</td>
<td>80.0 (IQR 80.0-90.0)</td>
<td>0.03</td>
</tr>
<tr>
<td><strong>Tumor characteristics</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tumor Size, cm</td>
<td>3.1±1.4 (59)</td>
<td>2.9±0.9 (60)</td>
<td>0.93</td>
</tr>
<tr>
<td>Tumor Stage</td>
<td></td>
<td></td>
<td>0.82</td>
</tr>
<tr>
<td>IA – T1 NO MO</td>
<td>11.9% (7/59)</td>
<td>5.0% (3/60)</td>
<td></td>
</tr>
<tr>
<td>IB – T2 NO MO</td>
<td>8.5% (5/59)</td>
<td>10.0% (6/60)</td>
<td></td>
</tr>
<tr>
<td>IIA – T3 NO MO</td>
<td>32.2% (19/59)</td>
<td>40.0% (24/60)</td>
<td></td>
</tr>
<tr>
<td>IIB – T1 N1 MO T2 N1 MO T3 N1 MO</td>
<td>25.4% (15/59)</td>
<td>25.0% (15/60)</td>
<td></td>
</tr>
<tr>
<td>III – T4 Any N M0</td>
<td>8.5% (5/59)</td>
<td>8.3% (5/60)</td>
<td></td>
</tr>
<tr>
<td>Unknown</td>
<td>13.6% (8/59)</td>
<td>11.7% (7/60)</td>
<td></td>
</tr>
<tr>
<td><strong>Procedure characteristics</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Technical Success</td>
<td>98.3% (58/59)</td>
<td>100% (60/60)</td>
<td>0.50</td>
</tr>
<tr>
<td>Biliary sphincterotomy</td>
<td>91.5% (54/59)</td>
<td>93.3% (56/60)</td>
<td>0.74</td>
</tr>
<tr>
<td>Characteristic</td>
<td>Prophylactic antibiotics</td>
<td>Stent Sizes</td>
<td>P-value</td>
</tr>
<tr>
<td>---------------</td>
<td>--------------------------</td>
<td>-------------</td>
<td>---------</td>
</tr>
<tr>
<td></td>
<td>47.5% (28/59)</td>
<td>46.7% (28/60)</td>
<td>0.99</td>
</tr>
<tr>
<td>Stent Sizes</td>
<td></td>
<td></td>
<td>0.52</td>
</tr>
<tr>
<td>8 mm x 4 cm</td>
<td>0% (0/59)</td>
<td>3.3% (2/60)</td>
<td></td>
</tr>
<tr>
<td>8 mm x 6 cm</td>
<td>1.7% (1/59)</td>
<td>0% (0/60)</td>
<td></td>
</tr>
<tr>
<td>8 mm x 8 cm</td>
<td>1.7% (1/59)</td>
<td>0% (0/60)</td>
<td></td>
</tr>
<tr>
<td>10 mm x 4 cm</td>
<td>23.7% (14/59)</td>
<td>26.7% (16/60)</td>
<td></td>
</tr>
<tr>
<td>10 mm x 6 cm</td>
<td>72.9% (43/59)</td>
<td>68.3% (41/60)</td>
<td></td>
</tr>
<tr>
<td>10 mm x 8 cm</td>
<td>0% (0/59)</td>
<td>1.7% (1/60)</td>
<td></td>
</tr>
</tbody>
</table>

Characteristics are presented as % (n) and medians with interquartile ranges (IQR).

Abbreviations: IQR, interquartile range; FC-SEMSs, fully-covered self-expanding metal stents; UC-SEMSs, uncovered self-expanding metal stents.
### Table 2. Key Outcomes.

<table>
<thead>
<tr>
<th>Effectiveness Outcome</th>
<th>FCSEMSs</th>
<th>UCSEMSs</th>
<th>( P ) value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sustained biliary drainage (Primary Endpoint)</td>
<td>72.2% (39/54)</td>
<td>72.9% (43/59)</td>
<td>0.01*</td>
</tr>
<tr>
<td>Neoadjuvant Therapy Not Completed**</td>
<td>18.2% (10/55)</td>
<td>28.8% (15/52)</td>
<td>0.25</td>
</tr>
<tr>
<td>Neoadjuvant Therapy Completed with Delay</td>
<td>16.4% (9/55)</td>
<td>11.5% (6/52)</td>
<td>0.58</td>
</tr>
<tr>
<td>With recurrent biliary obstruction requiring reintervention</td>
<td>3.6% (2/55)</td>
<td>1.9% (1/52)</td>
<td>0.99</td>
</tr>
<tr>
<td>Patients with CIS</td>
<td>43.6% (24/55)</td>
<td>45.8% (27/59)</td>
<td>0.58</td>
</tr>
<tr>
<td>SEMS Impacted surgical procedure</td>
<td>13.0% (3/24)</td>
<td>15.4% (4/27)</td>
<td>0.99</td>
</tr>
<tr>
<td>Median Time to CIS (N=50)</td>
<td>114.0 (IQR 90.5-168.5)</td>
<td>106.5 (IQR 83.0-211.0)</td>
<td>0.94</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Procedure-Related/Stent-Related Serious AEs</th>
<th>FCSEMS</th>
<th>UCSEMS</th>
<th>( P ) Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute cholecystitis</td>
<td>9.3% (4/43)</td>
<td>4.8% (2/42)</td>
<td>0.68</td>
</tr>
<tr>
<td>Acute pancreatitis***</td>
<td>1.7% (1/59)</td>
<td>0% (0/60)</td>
<td>0.50</td>
</tr>
<tr>
<td>Cholangitis</td>
<td>15.3% (9/59)</td>
<td>13.3% (8/60)</td>
<td>0.80</td>
</tr>
<tr>
<td>Gastrointestinal hemorrhage</td>
<td>1.7% (1/59)</td>
<td>0% (0/60)</td>
<td>0.50</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>1.7% (1/59)</td>
<td>3.3% (2/60)</td>
<td>0.99</td>
</tr>
<tr>
<td>CBD Obstruction or Abnormal LFTs</td>
<td>3.4% (2/59)</td>
<td>1.7% (1/60)</td>
<td>0.62</td>
</tr>
<tr>
<td>Liver abscess</td>
<td>0% (0/59)</td>
<td>1.7% (1/60)</td>
<td>0.99</td>
</tr>
<tr>
<td>Total</td>
<td>23.7% (14/59)</td>
<td>20.0% (12/60)</td>
<td>0.66</td>
</tr>
</tbody>
</table>

Abbreviations: FC-SEMSs, fully-covered self-expanding metal stents; UC-SEMSs, uncovered self-expanding metal stents.

*Noninferiority \( P \) value.

**None with recurrent biliary obstruction requiring reintervention

***Excludes reports of mild acute pancreatitis.
References


The figure shows a Kaplan-Meier survival curve comparing two groups (FC and UC) over time. The cumulative survival rate is plotted against time (in days), with the 95% confidence intervals shown. At each time point (90, 180, 365 days), the survival rates are given for both groups. The p-value for the difference in survival rates is 0.57.

At Risk:

- FC: 59, 55, 47, 36, 25
- UC: 60, 58, 46, 37, 27
Supplemental Appendix

Covered and uncovered biliary metal stents provide similar relief of biliary obstruction during neoadjuvant therapy in pancreatic cancer: a randomized trial

Short Title: Biliary metal stents in neoadjuvant therapy

Dong Wan Seo¹; Stuart Sherman²; Kulwinder S. Dua³; Adam Slivka⁴; Andre Roy⁵; Guido Costamagna⁶; Jacques Deviere⁷; Joyce Peetermans⁸; Matthew Rousseau⁸; Yousuke Nakai⁹; Hiroyuki Isayama⁹*, and Richard Kozarek¹⁰ for the “Biliary SEMS during neoadjuvant therapy study group”
Appendix 1.


- **Acute pancreatitis**: Abdominal pain and a serum concentration of pancreatic enzymes (amylase or lipase) three or more times the upper limit of normal, that required more than one night of hospitalization
- **Acute cholecystitis**: No suggestive clinical or radiographic signs of acute cholecystitis before the procedure and if emergency cholecystectomy is subsequently required
- **Perforation**: Retroperitoneal or bowel-wall perforation documented by any radiographic technique or direct visual evidence
- **Stent Occlusion**: Recurring obstructive jaundice with necessary stent replacement
- **Pancreaticojejunostomy leakage**: Drain output of any measurable volume of fluid on or after postoperative day 3 with an amylase content greater than 3 times the serum amylase activity, graded according to clinical course (ISGPS grade A, B, C), or direct visual evidence of defect at anastomosis
- **Delayed gastric emptying**: Gastric stasis requiring nasogastric intubation for 10 days or more, or the inability to tolerate a regular (solid) diet on or before the fourteenth postoperative day, not due to sequelae of intra-abdominal complications (ie, abscess, anastomotic leakage)
- **Biliary leakage**: Bilirubin in abdominal drain or dehiscence found at laparotomy
- **Gastro/-duodenojejunostomy leakage**: Conclusive radiographic or direct visual evidence of a defect of the anastomosis
- **Intra-abdominal abscess formation**: Intra-abdominal fluid collection with positive cultures identified by ultrasonography or computed tomography, associated with persistent fever and elevations of white blood cells
- **Wound infection**: Requiring intervention otherwise considered as minor adverse event
• **Portal Vein Thrombosis**: Conclusive radiologic evidence of thrombosis

• **Cholangitis**: Elevation in temperature more than 38°C, thought to have a biliary cause, without concomitant evidence of acute cholecystitis, requiring intervention

• **Hemorrhage**: Bleeding after the index procedure requiring transfusion of \( \geq 4 \) units of packed cells within a 24-hour period, or leading to relaparotomy/intervention

• **(Emergency) (re)laparotomy**: Any (other) reason after either preoperative biliary drainage or another surgical procedure

• **Pneumonia**: Pulmonary infection with radiological confirmation and requiring antibiotic treatment

• **Mortality**: In-hospital death, due to protocol adverse events or any cause, including progression of disease, within the study period
Supplementary Figure 1.
*Kaplan-Meier analysis of primary endpoint in patients who underwent curative intent surgery in the intention-to-treat analysis set.*

Kaplan-Meier curves are shown for sustained biliary drainage, according to randomized treatment arm in an ITT analysis for the subset of patients who underwent CIS. Sustained biliary drainage occurred in 83.3% of patients with FCSEMS versus 84.1% of patients with UCSEMS at 1 year ($P = .97$) in an analysis of N=51 patients who underwent CIS.

Abbreviations: CI, confidence interval; FC, fully covered; UC, uncovered.

Supplementary Figure 2.
*Kaplan-Meier analysis of primary endpoint in patients who did not undergo curative intent surgery in the intention-to-treat analysis set.*

Kaplan-Meier curves are shown for sustained biliary drainage, according to randomized treatment arm in an ITT analysis for the subset of patients who did not undergo CIS. Sustained biliary drainage occurred in 55.8% of patients with FCSEMS versus 47.0% of patients with UCSEMS at 1 year ($P = .84$) in an analysis of N=62 patients who did not undergo CIS.

Abbreviations: CI, confidence interval; FC, fully covered; UC, uncovered.

Supplementary Figure 3.
*Mean Bilirubin level as a function of follow-up visits*

Graph shows the mean Bilirubin level at 5 follow-up visits. Given that some patients underwent CIS and some did not, the number of patients per for whom the Bilirubin levels are documented varies per protocol at the various study visits. Specifically, the number of patients at each study visit in the graphic below is as follows: Baseline N=119, First preoperative visit N=111, Last pre-operative visit N=111, Transition to palliative management N=25, and One year after stent placement N=17.
Supplementary Table 1.

Reinterventions

Overall, 31 patients experienced an adverse event that required a reintervention during follow-up until CIS or 1 year if the patient could not undergo CIS.

Symptom was categorized into “Cholangitis,” “Biliary obstruction,” which included biliary obstructive symptoms and/or abnormal liver function tests without cholangitis, and “Acute cholecystitis.”

Cause was categorized into “Ingrowth” for tumor ingrowth into the SEMS, “Overgrowth” for hyperplastic or tumor overgrowth at the edges or extremity of the SEMS, “Migration” for partial distal or proximal migration or complete distal migration of the SEMS, “Presumed CD occlusion” reflecting the theoretical and presumed occlusion by the SEMS of the cystic duct confluence with the common bile duct, “Sludge,” which may have been further specified as sludge, necrotic debris, stones, or food impaction (causing succotash cholangitis in reintervention no. 26), “GI Bleed” in one case in setting of SEMS migration without biliary obstruction, and “Kinked SEMS” in one case of an UCSEMS having kinked after placement.

Intervention is self-explanatory. Second SEMS placed is applicable for reinterventions in which a SEMS is exchanged for another SEMS or in which a SEMS is placed inside of a SEMS.

<table>
<thead>
<tr>
<th>Reintervention Number</th>
<th>Group</th>
<th>GB in Situ</th>
<th>SEMS Length</th>
<th>Days to reintervention</th>
<th>Days to CIS</th>
<th>Cause</th>
<th>Symptom</th>
<th>Intervention</th>
<th>Type of Stent Placed</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>UC</td>
<td>Yes</td>
<td>6 cm</td>
<td>195</td>
<td>NA</td>
<td>Ingrowth</td>
<td>Cholangitis</td>
<td>Biliary RFA</td>
<td>N/A</td>
</tr>
<tr>
<td>2</td>
<td>UC</td>
<td>Yes</td>
<td>6 cm</td>
<td>168</td>
<td>NA</td>
<td>Ingrowth</td>
<td>Cholangitis</td>
<td>SEMS in SEMS</td>
<td>FC</td>
</tr>
<tr>
<td>3</td>
<td>UC</td>
<td>Yes</td>
<td>6 cm</td>
<td>160</td>
<td>NA</td>
<td>Ingrowth</td>
<td>Cholangitis</td>
<td>SEMS in SEMS</td>
<td>FC</td>
</tr>
<tr>
<td>4</td>
<td>UC</td>
<td>Yes</td>
<td>6 cm</td>
<td>331</td>
<td>NA</td>
<td>Ingrowth</td>
<td>Cholangitis</td>
<td>SEMS in SEMS</td>
<td>FC</td>
</tr>
<tr>
<td>5</td>
<td>UC</td>
<td>Yes</td>
<td>6 cm</td>
<td>213</td>
<td>NA</td>
<td>Ingrowth</td>
<td>Cholangitis</td>
<td>SEMS in SEMS</td>
<td>FC</td>
</tr>
<tr>
<td>6</td>
<td>UC</td>
<td>Yes</td>
<td>4 cm</td>
<td>14</td>
<td>152</td>
<td>Ingrowth</td>
<td>Biliary obstruction</td>
<td>SEMS in SEMS</td>
<td>FC</td>
</tr>
<tr>
<td>7</td>
<td>UC</td>
<td>Yes</td>
<td>4 cm</td>
<td>42</td>
<td>NA</td>
<td>Ingrowth</td>
<td>Biliary obstruction</td>
<td>SEMS in SEMS</td>
<td>FC</td>
</tr>
<tr>
<td>8</td>
<td>UC</td>
<td>Yes</td>
<td>4 cm</td>
<td>224</td>
<td>297</td>
<td>Ingrowth</td>
<td>Biliary obstruction</td>
<td>SEMS in SEMS</td>
<td>UC</td>
</tr>
<tr>
<td></td>
<td>UC</td>
<td>Yes</td>
<td>4 cm</td>
<td>227</td>
<td>NA</td>
<td>Ingrowth</td>
<td>Biliary obstruction</td>
<td>SEMS in SEMS</td>
<td>UC</td>
</tr>
<tr>
<td>---</td>
<td>----</td>
<td>-----</td>
<td>------</td>
<td>-----</td>
<td>----</td>
<td>----------</td>
<td>-------------------</td>
<td>-------------</td>
<td>----</td>
</tr>
<tr>
<td>10</td>
<td>UC</td>
<td>Yes</td>
<td>4 cm</td>
<td>73</td>
<td>83</td>
<td>Ingrowth</td>
<td>Biliary obstruction</td>
<td>PTBD</td>
<td>N/A</td>
</tr>
<tr>
<td>11</td>
<td>UC</td>
<td>Yes</td>
<td>8 cm</td>
<td>38</td>
<td>60</td>
<td>Presumed CD occlusion</td>
<td>Acute cholecystitis</td>
<td>Percutaneous cholecystostomy tube</td>
<td>N/A</td>
</tr>
<tr>
<td>12</td>
<td>UC</td>
<td>Yes</td>
<td>4 cm</td>
<td>24</td>
<td>NA</td>
<td>Presumed CD occlusion</td>
<td>Acute cholecystitis</td>
<td>Percutaneous cholecystostomy tube</td>
<td>N/A</td>
</tr>
<tr>
<td>13</td>
<td>UC</td>
<td>Yes</td>
<td>4 cm</td>
<td>10</td>
<td>NA</td>
<td>Sludge</td>
<td>Cholangitis</td>
<td>Sludge removal</td>
<td>N/A</td>
</tr>
<tr>
<td>14</td>
<td>UC</td>
<td>Yes</td>
<td>4 cm</td>
<td>203</td>
<td>NA</td>
<td>Overgrowth</td>
<td>Biliary obstruction</td>
<td>Plastic stent in SEMS</td>
<td>N/A</td>
</tr>
<tr>
<td>15</td>
<td>UC</td>
<td>Yes</td>
<td>6 cm</td>
<td>7</td>
<td>NA</td>
<td>Kinked SEMS</td>
<td>Cholangitis</td>
<td>SEMS in SEMS</td>
<td>PC</td>
</tr>
<tr>
<td>16</td>
<td>UC</td>
<td>Yes</td>
<td>4 cm</td>
<td>17</td>
<td>22</td>
<td>No observed SEMS occlusion or migration</td>
<td>Cholangitis</td>
<td>Naso-biliary drain</td>
<td>N/A</td>
</tr>
<tr>
<td>17</td>
<td>FC</td>
<td>Yes</td>
<td>6 cm</td>
<td>140</td>
<td>NA</td>
<td>Migration</td>
<td>Cholangitis</td>
<td>SEMS Exchange</td>
<td>UC</td>
</tr>
<tr>
<td>18</td>
<td>FC</td>
<td>Yes</td>
<td>4 cm</td>
<td>88</td>
<td>NA</td>
<td>Migration</td>
<td>Cholangitis</td>
<td>SEMS Exchange</td>
<td>UC</td>
</tr>
<tr>
<td>19</td>
<td>FC</td>
<td>Yes</td>
<td>6 cm</td>
<td>13</td>
<td>63</td>
<td>Migration</td>
<td>Cholangitis</td>
<td>FCSEMS removal, non-study SEMS placed</td>
<td>N/A</td>
</tr>
<tr>
<td>20</td>
<td>FC</td>
<td>Yes</td>
<td>6 cm</td>
<td>245</td>
<td>NA</td>
<td>Migration</td>
<td>Biliary obstruction</td>
<td>FCSEMS removal, plastic or non-study SEMS placed</td>
<td>N/A</td>
</tr>
<tr>
<td>21</td>
<td>FC</td>
<td>Yes</td>
<td>6 cm</td>
<td>204</td>
<td>NA</td>
<td>Migration</td>
<td>GI Bleed</td>
<td>SEMS Exchange</td>
<td>UC</td>
</tr>
<tr>
<td>22</td>
<td>FC</td>
<td>Yes</td>
<td>6 cm</td>
<td>7</td>
<td>110</td>
<td>Presumed CD occlusion</td>
<td>Acute cholecystitis</td>
<td>Percutaneous cholecystostomy tube</td>
<td>N/A</td>
</tr>
<tr>
<td>23</td>
<td>FC</td>
<td>Yes</td>
<td>4 cm</td>
<td>4</td>
<td>118</td>
<td>Presumed CD occlusion</td>
<td>Acute cholecystitis</td>
<td>SEMS Exchange</td>
<td>UC</td>
</tr>
<tr>
<td>24</td>
<td>FC</td>
<td>Yes</td>
<td>6 cm</td>
<td>53</td>
<td>NA</td>
<td>Presumed</td>
<td>Acute cholecystitis</td>
<td>Percutaneous</td>
<td>N/A</td>
</tr>
<tr>
<td></td>
<td>FC</td>
<td>Yes</td>
<td>6 cm</td>
<td>13</td>
<td>NA</td>
<td>CD occlusion</td>
<td>cholecystostomy tube</td>
<td></td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>----</td>
<td>-----</td>
<td>------</td>
<td>----</td>
<td>----</td>
<td>---------------------------------------</td>
<td>------------------------------------------</td>
<td>---</td>
<td></td>
</tr>
<tr>
<td>25</td>
<td>FC</td>
<td>Yes</td>
<td>6 cm</td>
<td>13</td>
<td>NA</td>
<td>Presumed CD occlusion</td>
<td>Acute cholecystitis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>26</td>
<td>FC</td>
<td>Yes</td>
<td>6 cm</td>
<td>22</td>
<td>NA</td>
<td>Sludge</td>
<td>Cholangitis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>27</td>
<td>FC</td>
<td>No</td>
<td>6 cm</td>
<td>147</td>
<td>NA</td>
<td>Sludge</td>
<td>Cholangitis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>28</td>
<td>FC</td>
<td>Yes</td>
<td>6 cm</td>
<td>168</td>
<td>NA</td>
<td>Sludge</td>
<td>Cholangitis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>29</td>
<td>FC</td>
<td>Yes</td>
<td>4 cm</td>
<td>204</td>
<td>NA</td>
<td>Sludge</td>
<td>Biliary obstruction</td>
<td></td>
<td></td>
</tr>
<tr>
<td>30</td>
<td>FC</td>
<td>Yes</td>
<td>4 cm</td>
<td>276</td>
<td>NA</td>
<td>Overgrowth</td>
<td>Biliary obstruction</td>
<td></td>
<td></td>
</tr>
<tr>
<td>31</td>
<td>FC</td>
<td>Yes</td>
<td>4 cm</td>
<td>3</td>
<td>91</td>
<td>No observed SEMS occlusion or migration</td>
<td>Progressive Jaundice</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: CD, cystic duct; FC, fully-covered; UC, uncovered; GI, gastrointestinal; N/A, not applicable; RFA, radio frequency ablation; SEMS, self-expanding metal stent; PC, partially covered; PTBD, percutaneous transhepatic biliary drain
Abbreviations:

CIS - curative intent surgery
CSEMS - covered self-expanding metal stents
EUS FNA/FNB - endoscopic ultrasound fine needle aspiration or fine needle biopsy
FCSEMS - fully-covered self-expanding metal stents
ITT - intention-to-treat
LFTs - liver function tests
NATx - neoadjuvant therapy
PD – pancreaticoduodenectomy
PP - per protocol
SEMS - self-expanding metal stents
UCSEMS - uncovered self-expanding metal stents
Clinical Trial Registration: ClinicalTrials.gov NCT02238847